Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the ...
The PD-1/PD-L1 market offers opportunities in therapy combinations, real-world data use, and digital patient support. With growth in specialty distribution channels, regional strategies, and ...
10hon MSN
FDA grants breakthrough status to Johnson & Johnson's cancer drug for advanced head and neck cancer
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...
The PD-1 and PD-L1 inhibitors market offers significant opportunities by expanding cancer treatment options using immunotherapy. Key developments include fast-track designations, successful trial ...
Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results